ICON PLC

Overview

ICON plc

type	Public
traded as	nasdaq: ICLR
industry	Contract research organization Pharmaceutical Medical device Life sciences Consulting
founded	1990 in Dublin, Ireland
founders	John Climax Ronan Lambe
hq location city	Dublin
hq location country	Ireland
key people	Barry Balfe (CEO) Nigel Clerkin (CFO)
products	Services for pharmaceutical, biotech and medical device industries
revenue	US$8.28 billion (2024)
net income	US$705.05 million (2024)
assets	US$16.88 billion (2024)
num employees	41,900
num employees year	2024
website	www.iconplc.com

ICON plc is an Irish headquartered multinational healthcare intelligence and clinical research organisation.[1] As of February 2025 had approximately 41,900 employees in 55 countries.[2]

History

ICON was founded in Dublin, Ireland, by John Climax and Ronan Lambe in 1990.[3] Since January 2010, Climax has held a position on the board of directors. Lambe retired from the board of directors in 2018.[4]

Between 1991 and 1996, ICON opened offices in the United Kingdom, United States, Germany, and Japan.[5] Two years later, ICON shares started to be traded on Nasdaq.[6]

Acquisitions

2000: ICON acquired UK-based regulatory consultancy, YRCR Ltd.; Central Laboratory in New York; and bioanalytical consultancy, Pacific Research[13][14][15]

2002: ICON acquired clinical research provider, BPA.[16]

2003: ICON acquired Medieval, a UK-based Phase I facility, and US consulting firm, Globomax [17][18]

2004: ICON acquired medical imaging specialist, Beacon Bioscience Inc.[19]

2006: ICON acquired outcomes research and health economics specialist, Ovation Research Group[20]

2007: ICON acquired European staffing group, DOCS International[21]

2008: ICON acquired US phase I provider, Healthcare Discoveries and US bioanalytical lab, Prevalere Life Sciences[22][23]

2009: ICON acquired Veeda Laboratories, a UK biomarker lab[24]

2010: ICON acquired Timaq Medical Imaging Inc.[25]

2011: ICON acquired Oxford Outcomes, an international health outcomes consultancy and Firecrest Clinical, a technology provider specialising in site performance and study management[26][27]

2012: ICON acquired PriceSpective, a global value strategy consultancy and Chinese CRO, BeijingWits[28][29]

2013: ICON acquired staffing and FSP providers, ClinForce and Assent and Akos, an EU provider of pharmacovigilance and drug safety services[30][31]

2014: ICON acquired Aptiv Solutions, a market leader in adaptive trial design and execution[32]

2015: ICON acquired MediMedia Pharma Solutions to enhance market access and scientific communications capabilities, and PMG Research Inc., an integrated network of clinical research sites in the US[33][34]

2016: ICON acquired Clinical Research Management Inc., to extend its presence in the government-sponsored research market[35]

2017: ICON acquired MAPI Group, thereby becoming the world's second-largest provider of late-phase services[36]

2019: ICON acquired Symphony Clinical Research, a leading provider of at-home patient services and site-support services; MediNova, an integrated network of clinical research sites across EMEA; and MolecularMD, to enhance its laboratory offerings in molecular diagnostic testing and immunohistochemistry[37][38][39]

2020: ICON acquired MedPass International, a leading European medical device CRO, regulatory and reimbursement consultancy[40]

2021: ICON acquired PRA Health Sciences, a competitor offering clinical research services, for US$12 billion. Upon completion of the transaction, PRA shareholders will own approximately 34 percent of the shares of the combined company and ICON shareholders will own approximately 66 percent.[41][42]

ICON PLC

History

Acquisitions

Finances

See also

External links

References